Senseonics Holdings, Inc. Reports Third Quarter 2026 Financial Results
Higher revenue and gross margin accompanied a wider quarterly loss as research and commercial expenses increased.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Senseonics Holdings (SENS) reported third-quarter 2026 revenue of $19.6 million, up approximately 140% year over year, and raised its annual outlook. U.S. revenue reached $16.8 million, while revenue outside the U.S. was $2.8 million. Gross margin rose to approximately 62% from 43%. Net loss widened to $32.7 million, or $0.50 per share, from $19.5 million, or $0.43 per share.
The company raised full-year revenue guidance to $68 million–$70 million from $62 million–$66 million and gross margin guidance to more than 60% from 58%–61%. Its Beta Bionics partnership targets an Eversense 365 integration with the iLet insulin delivery system, with launch planned for the fourth quarter of 2026, subject to integration activities and applicable requirements. Senseonics also initiated the first-in-human study of its investigational Freedom glucose monitoring system.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointThird-quarter revenue increased approximately 140% year over year to $19.6 million, from $8.1 million.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Full-year revenue guidance raised to $68 million–$70 million from $62 million–$66 million, implying 93%–98% annual growth.
- Moderate pointThird-quarter gross profit reached $12.1 million versus $3.5 million; margin rose to approximately 62% from 43%.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Full-year gross margin guidance raised to more than 60% from 58%–61%.
- Minor pointU.S. quarterly revenue rose approximately 160% to $16.8 million, with record quarterly shipment volume.
8 minor points
- Minor pointRevenue outside the U.S. increased approximately 65% to $2.8 million from $1.7 million.
- Minor pointActive prescribers increased approximately 90% year over year.
- Minor point. Forward-looking: it has not happened yet and may not happen.EON Care performed over 40% of quarterly insertions; its year-end inserter target increased to 120.
- Minor point. Forward-looking: it has not happened yet and may not happen.Beta Bionics partnership adds a planned fourth-quarter 2026 launch integrating Eversense 365 with iLet.
- Minor pointFreedom development advanced with initiation of a first-in-human study.
- Minor pointNine-month revenue increased to $45.756 million from $21.001 million in the prior-year period.
- Minor pointNine-month gross profit increased to $27.568 million from $8.094 million in the prior-year period.
- Minor pointCash, cash equivalents, restricted cash and short-term investments totaled $126.6 million at September 30, 2026.
Negative
- Moderate pointThird-quarter net loss widened to $32.7 million, or $0.50 per share, from $19.5 million, or $0.43.
- Moderate pointThird-quarter research and development expenses increased to $11.7 million from $7.8 million a year earlier.
- Moderate pointThird-quarter selling, general and administrative expenses increased to $32.3 million from $15.3 million a year earlier.
- Moderate pointThird-quarter operating loss widened to $31.856 million from $19.601 million a year earlier.
- Moderate pointCommon shares outstanding increased to 54,775,503 at September 30, 2026, from 41,265,778 at December 31, 2025.
8 minor points
- Minor pointThird-quarter interest expense increased to $1.813 million from $1.171 million a year earlier.
- Minor pointNine-month net loss widened to $101.715 million, or $1.80 per share, from $48.290 million, or $1.19.
- Minor pointNine-month research and development expenses rose to $31.917 million from $22.773 million a year earlier.
- Minor pointNine-month selling, general and administrative expenses rose to $95.341 million from $32.733 million a year earlier.
- Minor pointNine-month operating loss widened to $99.690 million from $47.412 million a year earlier.
- Minor pointNine-month interest expense increased to $4.606 million from $3.745 million a year earlier.
- Minor pointHercules facility debt carried at approximately $56.2 million, with $55.0 million principal outstanding at September 30, 2026.
- Minor pointBeta Bionics integration launch remains subject to completion of integration activities and applicable requirements.
News Explained
At September 30, cash, restricted cash and short-term investments totaled $126.6 million, above the $56.2 million debt carrying value.
In this completed third-quarter report, Senseonics records 54,775,503 common shares outstanding at
At
Details
Market Reaction – SENS
On Nov 10, the first trading day after this news, the latest delayed price for SENS is 14.08% above the previous close. Our momentum scanner has recorded 6 alerts for this stock so far that day. The latest delayed price is $11.18. Relative volume is exceptionally heavy at 15.3x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Revenue
- $19.6 million
- Q3 2026; versus $8.1 million in Q3 2025
- Full-year revenue guidance
- $68 million to $70 million
- 2026; raised from $62 million to $66 million
- Gross margin
- 62%
- Q3 2026; versus 43% in Q3 2025
- Full-year gross margin guidance
- More than 60%
- 2026; raised from 58% to 61%
- Net loss
- $32.7 million
- Q3 2026; compared with $19.5 million in Q3 2025
Previous Earnings Reports
-
Revenue grew and the company raised full-year revenue and gross-margin guidance.
-
Revenue increased year over year, gross profit turned positive, and net loss narrowed.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
continuous glucose monitoring (cgm) medical
first-in-human medical
automated insulin delivery (aid) technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Generated third quarter revenue of
$19.6 million , an increase of approximately140% year-over-year - Raised full-year 2026 revenue guidance to
$68 million to$70 million from$62 million to$66 million , representing year-over-year growth of93% to98% - Achieved gross margin of approximately
62% during Q3, and raising full-year gross margin guidance to more than60% from58% to61%
GERMANTOWN, Md., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a diabetes company redefining continuous glucose monitoring (CGM) with long-term implantable sensing technology, today announced third quarter 2026 financial results and provided a business update.
Recent Highlights & Accomplishments
- Drove third consecutive quarter of strong execution and performance since bringing U.S. Eversense® commercial operations in-house, delivering expansion of third quarter revenue to
$19.6 million and gross margins to approximately62% - U.S. third quarter revenue increased approximately
160% year-over-year to$16.8 million on record quarterly shipment volume, with active prescribers up approximately90% year-over-year - Grew the EON Care network to more than 100 inserters, who performed over
40% of third quarter Eversense insertion procedures; increased the target goal of EON Care inserters to 120 by year-end - Announced a strategic partnership with Beta Bionics to integrate Eversense 365 with the iLet® Bionic Pancreas automated insulin delivery system to support continued growth into 2027, with commercial launch planned for the fourth quarter of 2026, subject to completion of integration activities and applicable requirements
- Initiated the first-in-human study of Freedom, an investigational next-generation CGM system designed to communicate directly with a mobile device without any on-body component, building on the clinical experience and sensor technology shared with Eversense 365 and Gemini
“Our approximately
Brian Hansen, Chief Commercial Officer of Senseonics added, “Multiple initiatives to expand awareness and access create opportunities to bring Eversense to patients and prescribers we had not previously reached. As EON Care grows, we can extend our direct-to-consumer and health care provider outreach into additional markets with an insertion option already in place. We continue to build on our successful partnership with Sequel and the integration between Eversense 365 and twiist™ to reach patients seeking an AID solution. We expect our relationship with Beta Bionics to expand patient choice by pairing Eversense with another insulin delivery system. These efforts, together with our focus on commercial execution and continued direct-to-consumer outreach, position us to support broader adoption of Eversense 365.”
Third Quarter 2026 Results:
Total revenue for the third quarter of 2026 was
Third quarter 2026 gross profit was
Third quarter 2026 research and development expenses were
Third quarter 2026 selling, general and administrative expenses were
Net loss was
As of September 30, 2026, cash, cash equivalents, restricted cash and short-term investments totaled
Full Year 2026 Financial Outlook
Senseonics is raising its full-year 2026 global net revenue guidance to
Conference Call Information
Management will hold a conference call to review the Company’s third quarter 2026 performance starting today at 4:30 p.m. (Eastern Time). The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics’ website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-800-343-4136 (US/Canada) or 1-203-518-9843 (International), passcode SENSQ3, approximately five to ten minutes prior to start time.
About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a diabetes company redefining continuous glucose monitoring (CGM) with long-term implantable sensing technology. Driven by a mission to transform lives in the diabetes community, Senseonics is the maker of Eversense® 365, the world's first and only one-year CGM system, and is advancing a differentiated pipeline of innovation.
By commercializing Eversense 365 and pushing the boundaries of sensing technology, Senseonics is empowering better diabetes management, reducing the device burden, expanding patient choice, and shaping the future of diabetes care.
For more information, visit www.senseonics.com.
About Eversense
Eversense® 365 is the only long-term continuous glucose monitoring (CGM) system available, offering people with diabetes a truly differentiated CGM experience. Designed for people with diabetes who demand more, Eversense 365 combines a small sensor inserted under the skin by a healthcare provider with a removable smart transmitter that delivers real-time glucose data to a mobile app or an integrated Automated Insulin Delivery (AID) system. With a single sensor designed to last a full year, Eversense 365 provides a unique approach to CGM that supports health outcomes, enhances patient confidence, and minimizes the burden associated with short-term devices.
Eversense 365 is cleared in the U.S. and approved in Europe for people with diabetes aged 18 years and older, and is available by prescription only. The system is indicated for continually measuring glucose levels for up to 365 days, and for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions (fingerstick BG measurements are still required for calibration primarily one time per week after day 14, and when symptoms do not match CGM information or when taking medications of the tetracycline class). It is available in the U.S. and in select European markets. Patients should talk to their health care provider to learn more. For important safety information, visit https://www.eversensediabetes.com/safety-info/.
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for Senseonics, including the revenue and gross margin guidance under the heading “Full Year 2026 Financial Outlook” and expected geographic revenue mix; plans to expand the EON Care network and commercial outreach; anticipated benefits of commercial investments and initiatives; the continued roll-out of Eversense 365 in Europe; the anticipated timing and benefits of integrations with automated insulin delivery systems; future clinical development and intended functionality of Gemini and Freedom; future demand for and adoption of Eversense; and other statements containing the words “believe,” “expect,” “intend,” “may,” “could,” “projects,” “will,” “planned,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks and uncertainties related to demand, adoption, reimbursement, sales mix and costs affecting revenue and gross margins; the Company’s ability to expand its commercial infrastructure and achieve the anticipated benefits of its commercial initiatives; risks related to the continued commercial transition and roll-out of Eversense 365 in Europe, including the timing of tender updates; uncertainties in insurer, regulatory and administrative processes and decisions; uncertainties in clinical development, regulatory review, and successful commercialization of new technology and solutions, including Gemini and Freedom, including uncertainties resulting from the Company’s dependence on third parties within the Company’s development programs and supply chain; uncertainties in completing integrations, satisfying applicable requirements and coordinating with collaboration partners and other third parties; uncertainties inherent in the ongoing commercialization and expansion of Eversense and Senseonics’ and its partners’ activities; uncertainties relating to the current economic and regulatory/political environment, including the effects of tariffs; and such other factors as are set forth in the risk factors detailed in Senseonics’ Annual Report on Form 10-K for the year ended December 31, 2025 and quarterly reports on Form 10-Q filed with the SEC under the heading “Risk Factors.” The forward-looking statements included in this press release represent Senseonics’ views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics’ views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics’ views as of any date subsequent to the date hereof.
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com
| Senseonics Holdings, Inc. | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (in thousands, except share and per share data) | ||||||||
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 47,759 | $ | 40,234 | ||||
| Restricted cash | 315 | 315 | ||||||
| Short-term investments, net | 78,544 | 53,796 | ||||||
| Accounts receivable, net | 13,102 | 6,807 | ||||||
| Accounts receivable, net - related parties | — | 5,312 | ||||||
| Inventory, net | 8,439 | 6,703 | ||||||
| Prepaid expenses and other current assets | 4,741 | 4,366 | ||||||
| Total current assets | 152,900 | 117,533 | ||||||
| Deposits and other assets | 5,340 | 4,536 | ||||||
| Property, equipment and intangible assets, net | 4,267 | 4,200 | ||||||
| Total assets | $ | 162,507 | $ | 126,269 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 2,503 | $ | 4,059 | ||||
| Accrued expenses and other current liabilities | 20,209 | 15,091 | ||||||
| Accrued expenses and other current liabilities, related parties | 1,076 | 5,198 | ||||||
| Notes payable, current portion, net | 2,025 | — | ||||||
| Total current liabilities | 25,813 | 24,348 | ||||||
| Long-term debt and notes payable, net | 54,204 | 35,586 | ||||||
| Non-current operating lease liabilities | 4,869 | 5,289 | ||||||
| Total liabilities | 84,886 | 65,223 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Common stock, | 55 | 41 | ||||||
| Additional paid-in capital | 1,196,325 | 1,077,923 | ||||||
| Accumulated other comprehensive income (loss) | (57 | ) | 69 | |||||
| Accumulated deficit | (1,118,702 | ) | (1,016,987 | ) | ||||
| Total stockholders’ equity | 77,621 | 61,046 | ||||||
| Total liabilities and stockholders’ equity | $ | 162,507 | $ | 126,269 | ||||
| Senseonics Holdings, Inc. | ||||||||||||||||
| Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue, net | $ | 19,342 | $ | 4,202 | $ | 41,358 | $ | 9,235 | ||||||||
| Revenue, net - related parties | 219 | 3,893 | 4,398 | 11,766 | ||||||||||||
| Total revenue | 19,561 | 8,095 | 45,756 | 21,001 | ||||||||||||
| Cost of sales | 7,492 | 4,627 | 18,188 | 12,907 | ||||||||||||
| Gross profit | 12,069 | 3,468 | 27,568 | 8,094 | ||||||||||||
| Expenses: | ||||||||||||||||
| Research and development expenses | 11,667 | 7,759 | 31,917 | 22,773 | ||||||||||||
| Selling, general and administrative expenses | 32,258 | 15,310 | 95,341 | 32,733 | ||||||||||||
| Operating loss | (31,856 | ) | (19,601 | ) | (99,690 | ) | (47,412 | ) | ||||||||
| Other (expense) income, net: | ||||||||||||||||
| Interest income | 1,173 | 1,236 | 2,947 | 2,884 | ||||||||||||
| Interest expense | (1,813 | ) | (1,171 | ) | (4,606 | ) | (3,745 | ) | ||||||||
| Other (expense) income | (181 | ) | 6 | (366 | ) | (17 | ) | |||||||||
| Total other (expense) income, net | (821 | ) | 71 | (2,025 | ) | (878 | ) | |||||||||
| Net Loss | (32,677 | ) | (19,530 | ) | (101,715 | ) | (48,290 | ) | ||||||||
| Other comprehensive loss | ||||||||||||||||
| Translation adjustments | 35 | — | 66 | — | ||||||||||||
| Unrealized (loss) gain on marketable securities | (38 | ) | 65 | (192 | ) | 88 | ||||||||||
| Other comprehensive (loss) gain | (3 | ) | 65 | (126 | ) | 88 | ||||||||||
| Total comprehensive loss | $ | (32,680 | ) | $ | (19,465 | ) | $ | (101,841 | ) | $ | (48,202 | ) | ||||
| Basic net loss per common share | $ | (0.50 | ) | $ | (0.43 | ) | $ | (1.80 | ) | $ | (1.19 | ) | ||||
| Basic weighted-average shares outstanding | 65,736,278 | 44,953,694 | 56,569,410 | 40,554,943 | ||||||||||||
| Diluted net loss per common share | $ | (0.50 | ) | $ | (0.43 | ) | $ | (1.80 | ) | $ | (1.19 | ) | ||||
| Diluted weighted-average shares outstanding | 65,736,278 | 44,953,694 | 56,569,410 | 40,554,943 | ||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Senseonics' third-quarter 2026 revenue and net loss?
Senseonics generated $19.6 million in revenue and recorded a $32.7 million net loss, or $0.50 per share. Revenue increased approximately 140% year over year, while the net loss widened from $19.5 million, or $0.43 per share.
What is Senseonics' updated full-year 2026 guidance?
Senseonics expects full-year revenue of $68 million to $70 million and gross margin of more than 60%. The previous ranges were $62 million to $66 million and 58% to 61%, respectively. The updated revenue outlook represents year-over-year growth of 93% to 98%.
How much of Senseonics' 2026 revenue is expected to come from outside the United States?
Senseonics expects revenue outside the United States to represent approximately 15% of full-year 2026 revenue, reflecting the pace of U.S. outperformance. Commercial operations are now fully within Senseonics globally, and its dedicated commercial teams are leading Eversense 365 launches in European markets.
Why did Senseonics' third-quarter 2026 operating expenses increase?
Higher expenses reflected Gemini clinical trial activity and Freedom development, alongside ongoing commercial organization costs in the U.S. and Europe. Research and development expenses reached $11.7 million versus $7.8 million a year earlier; selling, general and administrative expenses reached $32.3 million versus $15.3 million.